SERNOVA Forum: Community User: COLOGNE79

LONDON, ONTARIO – September 17, 2019– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, announces that it has renewed the engagement of Frontier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services. Sernova President and CEO Dr. Philip Toleikis commented, "Frontier remains an integral part of the communications strategy Sernova is implementing to increase Sernova’s visibility and help investors and shareholders stay well-informed as we advance our clinical programs including our US diabetes Phase I/II clinical study.” Through their established network of financial industry professionals, marketing service providers, and outreach programs, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media distribution on national television, radio and multiple online channels. Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $100,000 plus expenses. The agreement with Frontier Flex is subject to the approval of the TSX Venture Exchange. In other news, Sernova has granted 6,980,000 stock options to certain officers, employees, and consultants of the company, each such option being exercisable into one common share at a price of $0.21 per share for periods ranging from 3 to 10 years, and has granted 3,120,167 DSUs to its directors.

Hatten wir ja lange nicht mehr. Genießt den Anblick😂

0,15🎉🎈

Da gibt es mehrere, vor allem kanadische Investmentbanken, die Aktien aufkaufen aber auch wieder abstoßen. Keine Ahnung was die damit machen.

Gr*ruppe?

Die Investment ***?

Hampton - aggressiver Käufer bei SVA

LONDON, ONTARIO –September 10, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which Sernova issued a total of 23,422,822 Units in three closings (August 16, 2019, August 30, 2019, and September 9, 2019). Net proceeds from the private placement will be used to support funding of Sernova's clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial, “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch(TM) for Clinical Islet Transplantation” and to advance internal preclinical development programs and corporate/academic collaborations utilizing the Company’s platform technologies to treat diabetes, hemophilia and other serious disease conditions, as well as for investor relations and general corporate purposes. Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one common share purchase warrant (“Warrant”). Each Warrant will be exercisable into one share at a price of $0.30 per share for a period of 36 months. The private placement has received approval of the TSX Venture Exchange. Pursuant to applicable Canadian securities laws, the securities issued under the Private Placement are subject to a four-month hold period from the time of closing of the Private Placement. The hold periods for this Private Placement expire on December 17, 2019, December 31, 2019, and January 10, 2020. The Company compensated finders by way of cash fees of $78,225 and 391,125 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. About Sernova’s US Clinical Study The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch. A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be *** with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures. For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.

LONDON, ONTARIO –September 10, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which Sernova issued a total of 23,422,822 Units in three closings (August 16, 2019, August 30, 2019, and September 9, 2019). Net proceeds from the private placement will be used to support funding of Sernova's clinical program including its FDA cleared US Phase I/II regenerative medicine clinical trial, “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch(TM) for Clinical Islet Transplantation” and to advance internal preclinical development programs and corporate/academic collaborations utilizing the Company’s platform technologies to treat diabetes, hemophilia and other serious disease conditions, as well as for investor relations and general corporate purposes. Each Unit in the Offering is priced at $0.20 per Unit and consists of one common share and one common share purchase warrant (“Warrant”). Each Warrant will be exercisable into one share at a price of $0.30 per share for a period of 36 months. The private placement has received approval of the TSX Venture Exchange. Pursuant to applicable Canadian securities laws, the securities issued under the Private Placement are subject to a four-month hold period from the time of closing of the Private Placement. The hold periods for this Private Placement expire on December 17, 2019, December 31, 2019, and January 10, 2020. The Company compensated finders by way of cash fees of $78,225 and 391,125 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. About Sernova’s US Clinical Study The approved protocol is a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch. A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be *** with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures. For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.

Sernova Completes Oversubscribed Private Placement of $4,684,564

Aber das bei Semma verstehe ich nicht. Der Ansatz mit den Zellen ist identisch mit Sernova. Semma erklärt jedoch nicht, wie die Zellen in den Körper abgegeben werden. Und das macht ja Sernovas Cell Pouch eigentlich so einzigartig.

Trotzdem hatte ich erst auf Viacyte getippt.

Oh man. Ich bin so gespannt was mit Sernova passiert.

Hab’s gerade entdeckt. Semma. Vor allem testen die noch nicht mal am Menschen?! Wie geht das? 1Milliarde🤑

https://www.google.de/amp/s/www.evaluate.com/node/15042/amp

Tycoon. Das ist mal ein bull shit, auf das ich nicht böse bin😄